<DOC>
	<DOCNO>NCT00441909</DOCNO>
	<brief_summary>Vaginal microbicides compound may protect woman HIV sexually transmit infection ( STIs ) . This study determine safety microbicide UC-781 compare effect keep microbicide vagina different lengths time .</brief_summary>
	<brief_title>Phase I Study Safety Persistence UC-781 Vaginal Microbicide</brief_title>
	<detailed_description>Vaginal microbicides compound apply inside vagina may protect woman vaginal transmission HIV STIs . This study evaluate safety vaginal microbicide UC-781 . Studies show UC-781 effective inhibitor HIV-1 reverse transcriptase . UC-781 test animal model Phase I II study human . The result study indicate cervical tissue fully protect different variant HIV . The purpose study assess incidence epithelial disruption inflammation cervix , vagina , vulva healthy HIV uninfected woman single exposure UC-781 vaginal gel . This study compare result leave microbicide vagina vary lengths time . The duration study approximately 35 day . Participants study randomly assign one eight group , participant receive single exposure UC-781 placebo gel . There five total study visit , include screen study entry visit . Screening occur approximately 10 day prior study entry visit . At study entry , single application microbicide placebo gel insert 0 , 2 , 4 , 8 hour vagina . Length exposure time differ , depend group participant randomly assign . Following vaginal exposure microbicide , microbicide rinse . Vaginal secretion collect test antiviral activity HIV ass amount microbicide remain vagina . Visits 3 5 occur approximately 24 48 hour , 6 8 day , 25 35 day follow study entry . At visit , participant ask complete questionnaire undergo pelvic exam , STI test , vital sign measurement . Blood urine collection occur visit . On select visit , colposcopy conduct participant interview regard product acceptability , addition measure . Between select visit , participant ask maintain sexual abstinence use condom .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Inclusion Criteria Screening Visit : HIV uninfected General good health Normal Pap smear within 12 month prior screen obtain screen visit Anatomy lend easily visualization cervix Sexual abstinence ( include vaginal , oral , rectal ) Visit 1 completion Visit 4 Agree use condom provide study Visits 4 5 Agree abstain use intravaginal product vaginal penetration throughout study Willing use acceptable form contraception completion study Willing participate studyrelated assessment follow studyrelated procedure Inclusion Criteria Study Entry : Meet inclusion criterion screen visit Study Entry Willing stay MageeWomens Hospital Clinical Research Center ( MWH CRC ) 9 hour gel insertion Exclusion Criteria Screening Visit : Menopause ( least 12 month without menses absence longacting progestin use ) Hysterectomy Latex allergy Use diaphragm , NuvaRing , spermicide contraception Diagnosed urogenital infection suspect infection 21 day prior study screen . More information criterion find protocol . Menses vaginal bleeding anticipate 17 day postscreening Antibiotic antifungal therapy ( vaginal systemic ) 14 day prior study screen Injected nontherapeutic drug 12 month prior study screen Systemic immunosuppressive drug use 60 day prior study screen Participation drug , spermicide , and/or microbicide study 30 day prior study screen Any condition , opinion investigator , would interfere study Intravaginal use device product ( except tampon ) 7 day prior study screen Surgical procedure involve pelvis 90 day prior enrollment ( e.g. , dilation curettage evacuation , cervical biopsy , cryosurgery , surgery involve pelvic organ area ) Abnormal pelvic exam finding , opinion investigator would complicate interpretation colposcopy Pregnancy , within 90 day last pregnancy Breastfeeding Exclusion Criteria Study Entry : Meets exclusion criterion screen visit Diagnosed suspected reproductive tract infection urinary tract infection . More information criterion find protocol . Menses vaginal bleeding anticipate 8 day follow study entry Injected nontherapeutic drug study screen study entry Certain abnormal laboratory value</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Anti-Infective Agents , Local</keyword>
	<keyword>Healthy Women</keyword>
	<keyword>Microbicides</keyword>
	<keyword>UC-781</keyword>
	<keyword>Vaginal Gel</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>